CN112089054A - 降血糖益生菌组合物 - Google Patents
降血糖益生菌组合物 Download PDFInfo
- Publication number
- CN112089054A CN112089054A CN202011004485.3A CN202011004485A CN112089054A CN 112089054 A CN112089054 A CN 112089054A CN 202011004485 A CN202011004485 A CN 202011004485A CN 112089054 A CN112089054 A CN 112089054A
- Authority
- CN
- China
- Prior art keywords
- lactobacillus
- day
- cfu
- lactobacillus reuteri
- lactobacillus salivarius
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000006041 probiotic Substances 0.000 title claims abstract description 22
- 235000018291 probiotics Nutrition 0.000 title claims abstract description 22
- 239000000203 mixture Substances 0.000 title claims abstract description 21
- 230000000529 probiotic effect Effects 0.000 title claims abstract description 17
- 239000008280 blood Substances 0.000 title abstract description 34
- 210000004369 blood Anatomy 0.000 title abstract description 34
- 241000186604 Lactobacillus reuteri Species 0.000 claims abstract description 33
- 241000186869 Lactobacillus salivarius Species 0.000 claims abstract description 33
- 229940001882 lactobacillus reuteri Drugs 0.000 claims abstract description 33
- 239000000843 powder Substances 0.000 claims abstract description 31
- 244000302512 Momordica charantia Species 0.000 claims abstract description 24
- 235000009811 Momordica charantia Nutrition 0.000 claims abstract description 24
- 235000009812 Momordica cochinchinensis Nutrition 0.000 claims abstract description 17
- 235000018365 Momordica dioica Nutrition 0.000 claims abstract description 17
- 230000002218 hypoglycaemic effect Effects 0.000 claims abstract description 9
- 235000015872 dietary supplement Nutrition 0.000 claims abstract description 5
- 230000001580 bacterial effect Effects 0.000 claims description 10
- 235000013336 milk Nutrition 0.000 claims description 10
- 239000008267 milk Substances 0.000 claims description 10
- 210000004080 milk Anatomy 0.000 claims description 10
- 244000068988 Glycine max Species 0.000 claims description 4
- 235000010469 Glycine max Nutrition 0.000 claims description 4
- 241000186660 Lactobacillus Species 0.000 claims description 4
- 229940039696 lactobacillus Drugs 0.000 claims description 4
- 235000013618 yogurt Nutrition 0.000 claims description 4
- 241001465754 Metazoa Species 0.000 claims description 2
- 235000008452 baby food Nutrition 0.000 claims description 2
- 235000013351 cheese Nutrition 0.000 claims description 2
- 235000009508 confectionery Nutrition 0.000 claims description 2
- 235000021185 dessert Nutrition 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 235000019985 fermented beverage Nutrition 0.000 claims description 2
- 239000012530 fluid Substances 0.000 claims description 2
- 235000015203 fruit juice Nutrition 0.000 claims description 2
- 235000013402 health food Nutrition 0.000 claims description 2
- 235000015243 ice cream Nutrition 0.000 claims description 2
- 235000015110 jellies Nutrition 0.000 claims description 2
- 239000008274 jelly Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 235000011496 sports drink Nutrition 0.000 claims description 2
- 235000015192 vegetable juice Nutrition 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract description 22
- 239000008103 glucose Substances 0.000 abstract description 22
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract description 22
- 239000003814 drug Substances 0.000 abstract description 18
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 abstract description 6
- 230000006378 damage Effects 0.000 abstract description 6
- 238000010521 absorption reaction Methods 0.000 abstract description 5
- 150000001720 carbohydrates Chemical class 0.000 abstract description 5
- 210000004185 liver Anatomy 0.000 abstract description 5
- 230000004060 metabolic process Effects 0.000 abstract description 5
- 150000002772 monosaccharides Chemical class 0.000 abstract description 5
- 229930091371 Fructose Natural products 0.000 abstract description 4
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 abstract description 4
- 239000005715 Fructose Substances 0.000 abstract description 4
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 abstract description 4
- 229930182830 galactose Natural products 0.000 abstract description 4
- 210000003734 kidney Anatomy 0.000 abstract description 4
- 230000002829 reductive effect Effects 0.000 abstract description 4
- 235000013305 food Nutrition 0.000 abstract description 3
- 210000004347 intestinal mucosa Anatomy 0.000 abstract description 3
- 230000015556 catabolic process Effects 0.000 abstract description 2
- 238000006731 degradation reaction Methods 0.000 abstract description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 19
- 206010012601 diabetes mellitus Diseases 0.000 description 16
- 230000000968 intestinal effect Effects 0.000 description 12
- 229940125396 insulin Drugs 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 102000004877 Insulin Human genes 0.000 description 8
- 108090001061 Insulin Proteins 0.000 description 8
- 206010022489 Insulin Resistance Diseases 0.000 description 6
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 6
- 229960003105 metformin Drugs 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- 239000002158 endotoxin Substances 0.000 description 5
- 210000001035 gastrointestinal tract Anatomy 0.000 description 5
- 235000008322 Trichosanthes cucumerina Nutrition 0.000 description 4
- 229920006008 lipopolysaccharide Polymers 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 241000700159 Rattus Species 0.000 description 3
- 108091006300 SLC2A4 Proteins 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 235000009200 high fat diet Nutrition 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 239000000902 placebo Substances 0.000 description 3
- 229940068196 placebo Drugs 0.000 description 3
- 102000019034 Chemokines Human genes 0.000 description 2
- 108010012236 Chemokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 2
- 201000008980 hyperinsulinism Diseases 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000008798 inflammatory stress Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 235000013406 prebiotics Nutrition 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 2
- 229960001052 streptozocin Drugs 0.000 description 2
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 102000002029 Claudin Human genes 0.000 description 1
- 108050009302 Claudin Proteins 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 206010012655 Diabetic complications Diseases 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 208000037487 Endotoxemia Diseases 0.000 description 1
- 102000058061 Glucose Transporter Type 4 Human genes 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 108091006301 SLC2A5 Proteins 0.000 description 1
- 108091006277 SLC5A1 Proteins 0.000 description 1
- 102000058090 Sodium-Glucose Transporter 1 Human genes 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229940009289 bifidobacterium lactis Drugs 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 230000004136 fatty acid synthesis Effects 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 239000003629 gastrointestinal hormone Substances 0.000 description 1
- 230000004110 gluconeogenesis Effects 0.000 description 1
- 230000014101 glucose homeostasis Effects 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 230000006377 glucose transport Effects 0.000 description 1
- 230000004190 glucose uptake Effects 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000006575 hypertriglyceridemia Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000002473 insulinotropic effect Effects 0.000 description 1
- 230000003870 intestinal permeability Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000013586 microbial product Substances 0.000 description 1
- 208000015994 miscarriage Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 230000016379 mucosal immune response Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 238000013116 obese mouse model Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000027758 ovulation cycle Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 229940126673 western medicines Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/173—Reuteri
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/181—Salivarius
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Diabetes (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Epidemiology (AREA)
- Food Science & Technology (AREA)
- Endocrinology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
本发明公开了降血糖益生菌组合物，属于益生菌的所有相关食品产业领域。它包括唾液乳杆菌、罗伊氏乳杆菌和苦瓜粉。本发明中降血糖益生菌组合物组合物，有着高效的单糖利用率，并能减少肠道黏膜细胞对葡糖糖、半乳糖、果糖的吸收，降低血糖浓度。同时，显著改善葡萄糖的代谢情况和血脂水平和含量，减轻二型糖尿病对肝脏和肾脏的损伤。是一种能长期安全服用的，降低机体对糖类物质的吸收与利用，提高糖类降解代谢，改善二型糖尿病对机体伤害之食品补充或药物。
Description
技术领域
本发明涉及降血糖益生菌组合物，属于益生菌的所有相关食品产业领域。
背景技术
根据世界卫生组织的数据，全球糖尿病（diabetes）疾病的发病率约占人口数量的10%，在部分地区甚至高达33%。导致糖尿病的病因有很多，包括遗传和环境因素，占非传染性慢性疾病死亡病例的3.5%（WHO, 2016）。科学证据表明，胰岛素（insulin）耐受导致机体炎症应激的增加，肠道菌群与环境、遗传因素的相互影响导致了糖尿病的发生（Cani P Det al，2005）。
人的肠胃道腔内平均每毫升含有1014个，超过5000种微生物。研究表明，肠道菌群组成与过敏、肠道炎性疾病、癌症、糖尿病、心血管疾病和血脂异常等情况有关（Holmes E,2011; Larsen N, 2010）。肠道微生物通过多种分子机制对2型糖尿病（type 2 diabetes，T2D）产生影响。T2D与促炎细胞因子、趋化因子和炎症蛋白水平升高有关。一些肠道微生物和微生物产物，特别是脂多糖（lipopolysaccharide，LPS）能够降低炎症反应，刺激产生抗炎细胞因子和趋化因子（Gurung M，2020）。另外，由于紧密连接蛋白表达减少，导致细菌脂多糖（LPS）易位，进而导致肠道通透性和黏膜免疫反应的增加，这可能导致代谢性内毒素血症和胰岛素抵抗（Cani PD, 2008; Secondulfo M, 2004）。肠道菌群还可能通过影响肝脏、肌肉和脂肪等主要代谢器官的葡萄糖稳态和胰岛素抵抗，以及通过影响糖的消化和控制这一过程的肠道激素的产生来影响T2D（Gurung M，2020）。研究表明，乳酸双歧杆菌可以增加糖原合成，降低与葡萄糖异生相关的肝脏基因表达；同时改善了葡萄糖转运体4 （glucosetransporter-4，GLUT4）对葡萄糖的转运和刺激胰岛素对葡萄糖的摄取（Kim SH，2014）。增加脂肪酸的氧化和能量消耗以及减少脂肪酸的合成可以改善肥胖，从而改善T2D（HoumardJA, 2008）。益生菌对肠道菌群的调节可以促进一些临床疾病的改善，也被认为是胰岛素抵抗治疗中有效的佐剂。（Moroti C, 2012）研究表明，链脲佐菌素（streptozotocin）诱导的糖尿病小鼠，联合使用益生元和二甲双胍（metformin），与单用二甲双胍相比，联合用药可改善空腹血糖、葡萄糖耐量和胰岛素抵抗（Zheng J, 2018）。在一项随机双盲试验中，二甲双胍治疗T2D患者4个月后，对肠道菌群有很强的影响；安慰剂组转换成二甲双胍继续治疗2个月后，对肠道菌群影响也很大。将二甲双胍治疗后的粪便菌群移植后无菌小鼠后，小鼠葡萄糖耐受得到改善（Wu H，2017）。
为了筛选对T2D有干预潜力的益生菌菌株，体外研究测试了20株天然乳酸菌菌株并评估他们对单糖的分解能力。结果表明，唾液乳杆菌Lactobacillus salivarius AP-32和罗伊氏乳杆菌Lactobacillus reuteri GL-104有着优秀的单糖（葡萄糖）和混合单糖（葡萄糖、果糖和半乳糖）利用率。AP-32和GL-104能够抑制转运蛋白SGLT1和GLUT5基因的表达，从而减少葡萄糖、半乳糖、果糖从肠道中被肠粘膜细胞吸收进入血液，降低血糖浓度。进一步的实验表明，AP-32和GL-104可显著改善糖尿病小鼠的葡萄糖代谢，改善糖尿病小鼠的血脂水平和含量。同时，AP-32和GL-104联合使用，可显著改善T2D对肝脏和肾脏的损伤（HsiehP S，2020）。
苦瓜是一种复杂的却又不同寻常的植物药物，它不仅被广泛用作食物，而且在治疗糖尿病、牛皮癣和感染、调节月经周期、治疗不孕症和诱导流产等疾病方面也有着悠久的历史。苦瓜中含有一种蛋白质，在结构和药理上与胰岛素相似，它通常被称为v-胰岛素。在一项小型研究中，9例患者(6例为少年期发病，1例为成熟期发病，2例为无症状型糖尿病)皮下注射v-胰岛素。5例健康和5例明显糖尿病患者作为对照组，给予安慰剂注射。治疗组的降糖效果在注射后30 - 60分钟开始，且血糖浓度达到高峰的时间也显著低于常规时间（Baldwa VS，1977）。苦瓜富含膳食纤维和其他生物活性化合物，给肥胖大鼠喂食高脂饮食（HFD）并用苦瓜粉（BMP）处理8周；与HFD组相比，BMP有效延缓体重增加和提高胰岛素敏感性，降低内毒素负荷；BMP改变了肠道菌群，也改变了代谢谱，包括有机酸、氨基酸和糖类的代谢；在肥胖小鼠中，BMP通过恢复肠道菌群和肠道代谢产物发挥抑制胰岛素抵抗和抗炎作用（Bai J，2018）。苦瓜的另一个特点是它可以减轻糖尿病并发症。糖尿病与肾脏、眼睛、神经和血管的不可逆转的功能和结构变化有关，而苦瓜在各种动物模型中可能减轻这些并发症的某些方面。在三高综合征（高血糖与高胰岛素血症、高甘油三酯血症和肥胖相关）大鼠模型中，苦瓜提取物喂养的试验组大鼠，与对照组大鼠相比，可防止高胰岛素血症和高血糖（Grover JK，2004）。
全世界有约十分之一的人口饱受糖尿病的困扰。科学证据表明，胰岛素（insulin）耐受导致机体炎症应激的增加，肠道菌群与环境、遗传因素的相互影响导致了糖尿病的发生。目前临床上对糖尿病的治疗方案，多为口服或者注射促胰岛素分泌剂、胰岛素类似物或者胰岛血糖素抑制剂等。长期药物的使用，会导致机体对胰岛素出现耐受，使得药物逐渐没有效果，更不能改善并发症对机体的危害。因此，迫切需要一个安全、有效、无耐药风险的针对2型糖尿病的解决方案。近年来，药物（例如二甲双胍）和肠道菌群的相互作用受到了极大的关注。通过益生菌、益生元改变肠道菌群可能更加安全有效地影响糖尿病药物的效果。
发明内容
本发明所要解决的技术问题在于：提供降血糖益生菌组合物，作为有效、安全、不复发改善机体二型糖尿病的食品补充或药物的方法，解决降血糖相关市场上急需解决的问题。
本发明所要解决的技术问题采取以下技术方案来实现：
降血糖益生菌组合物，包括唾液乳杆菌、罗伊氏乳杆菌合并苦瓜粉，有效量为每日合并补充100亿～500亿唾液乳杆菌、罗伊氏乳杆菌，即0.5*1010 cfu/day～2.5*1010 cfu/day的唾液乳杆菌菌量和0.5*1010 cfu/day～2.5*1010 cfu/day的罗伊氏乳杆菌菌量，每日0.5克～2.5克苦瓜粉。
作为优选实例，所述唾液乳杆菌为唾液乳杆菌AP-32、罗伊氏乳杆菌为罗伊氏乳杆菌GL-104。。
作为优选实例，所述唾液乳杆菌、罗伊氏乳杆菌合并苦瓜粉的有效量为每日补充100亿，即0.5*1010 cfu/day的唾液乳杆菌和0.5*1010 cfu/day的罗伊氏乳杆菌菌量以及每日0.5克苦瓜粉。
作为优选实例，所述唾液乳杆菌、罗伊氏乳杆菌合并苦瓜粉可进一步包括药学上可接受之载剂、赋形剂或稀释剂；并可进一步制成流体乳品、浓缩牛奶、优酪乳、酸乳、冷冻优格、乳杆菌发酵饮料、奶粉、冰淇淋、乳酪、干酪、豆浆、发酵豆浆、蔬果汁、果汁、运动饮料、甜点、果冻、糖果、婴儿食品、健康食品、动物饲料、中草药组合物或膳食补充品。
本发明的有益效果是：本发明中的唾液乳杆菌、罗伊氏乳杆菌合并苦瓜粉，通过益生菌有效降低血糖，并组合降血糖因子苦瓜粉。有着高效的单糖利用率，并能减少肠道黏膜细胞对葡糖糖、半乳糖、果糖的吸收，降低血糖浓度。同时，显著改善葡萄糖的代谢情况和血脂水平和含量，减轻二型糖尿病对肝脏和肾脏的损伤。是一种能长期安全服用的，降低机体对糖类物质的吸收与利用，提高糖类降解代谢，改善二型糖尿病对机体伤害之食品补充或药物。
具体实施方式
为了对本发明的技术手段、创作特征、达成目的与功效易于明白了解，下面结合具体实施例，进一步阐述本发明。
实施例一
降血糖益生菌组合物，包括唾液乳杆菌、罗伊氏乳杆菌合并苦瓜粉，所述唾液乳杆菌、罗伊氏乳杆菌合并苦瓜粉的有效量为每日补充100亿，即0.5*1010 cfu/day的唾液乳杆菌和0.5*1010 cfu/day的罗伊氏乳杆菌菌量以及每日0.5克苦瓜粉。
实施例二
降血糖益生菌组合物，包括唾液乳杆菌、罗伊氏乳杆菌合并苦瓜粉，所述唾液乳杆菌、罗伊氏乳杆菌合并苦瓜粉的有效量为每日补充100亿，即1.0*1010 cfu/day的唾液乳杆菌和1.0*1010 cfu/day的罗伊氏乳杆菌菌量以及每日1.0克苦瓜粉。
实施例三
降血糖益生菌组合物，包括唾液乳杆菌、罗伊氏乳杆菌合并苦瓜粉，所述唾液乳杆菌、罗伊氏乳杆菌合并苦瓜粉的有效量为每日补充100亿，即1.5*1010 cfu/day的唾液乳杆菌和1.5*1010 cfu/day的罗伊氏乳杆菌菌量以及每日1.5克苦瓜粉。
实施例四
降血糖益生菌组合物，包括唾液乳杆菌、罗伊氏乳杆菌合并苦瓜粉，所述唾液乳杆菌、罗伊氏乳杆菌合并苦瓜粉的有效量为每日补充100亿，即2.0*1010 cfu/day的唾液乳杆菌和2.0*1010 cfu/day的罗伊氏乳杆菌菌量以及每日2.0克苦瓜粉。
实施例五
降血糖益生菌组合物，包括唾液乳杆菌、罗伊氏乳杆菌合并苦瓜粉，所述唾液乳杆菌、罗伊氏乳杆菌合并苦瓜粉的有效量为每日补充100亿，即2.5*1010 cfu/day的唾液乳杆菌和2.5*1010 cfu/day的罗伊氏乳杆菌菌量以及每日2.5克苦瓜粉。
研究方法及进行步骤
1.临床试验
选取60名年龄在18-60岁的患有二型糖尿病患者，男女不限；
随机分为试验组50例和对照组10例，试验组按照上述五个实施例（每组10例）服用本品，对照组口服安慰剂一个月；
试验组连续试用一个月，并随后停止试用再追踪观察一个月；
试用期间不使用其它降血糖的中西药物及疗法，追踪观察试验者服用本品1天前、服用药物30天后和服用药物60天后空腹血糖指标。
疗效判断标准：
(1)显效: 服用药物30天后的空腹血糖指标显著低于服用本品1天前水平，服用药物60天后的空腹血糖指标与服用药物30天后的空腹血糖指标无显著性差异；
(2)有效: 服用药物30天后的空腹血糖指标显著低于服用本品1天前水平，服用药物60天后的空腹血糖指标与服用药物30天后的空腹血糖指标有显著性差异，并接近于服用本品1天前水平；
(3)无效: 服用药物30天后的空腹血糖指标与服用本品1天前水平无显著性差异；
按照以上降血糖疗效标准观察效果，结果表明，本发明的组合物能够显著改善二型糖尿病患者的血糖水平，相比降血糖药物，本组合物安全有效，有助于二型糖尿病的治疗和维护。
以上显示和描述了本发明的基本原理和主要特征和本发明的优点。本行业的技术人员应该了解，本发明不受上述实施例的限制，在不脱离本发明精神和范围的前提下，本发明还会有各种变化和改进，这些变化和改进都落入要求保护的本发明范围内。本发明要求保护范围由所附的权利要求书及其等效物界定。
Claims (4)
1.降血糖益生菌组合物，其特征在于：包括唾液乳杆菌、罗伊氏乳杆菌和苦瓜粉，有效量为每日合并补充100亿～500亿唾液乳杆菌、罗伊氏乳杆菌，即0.5*1010 cfu/day～2.5*1010 cfu/day的唾液乳杆菌菌量和0.5*1010 cfu/day～2.5*1010 cfu/day的罗伊氏乳杆菌菌量，每日0.5克～2.5克苦瓜粉。
2.根据权利要求1所述的降血糖益生菌组合物，其特征在于：所述唾液乳杆菌为唾液乳杆菌AP-32、罗伊氏乳杆菌为罗伊氏乳杆菌GL-104。
3.根据权利要求1所述的降血糖益生菌组合物，其特征在于：唾液乳杆菌、罗伊氏乳杆菌合并苦瓜粉的有效量为每日补充100亿，即0.5*1010 cfu/day的唾液乳杆菌和0.5*1010cfu/day的罗伊氏乳杆菌菌量以及每日0.5克苦瓜粉。
4.根据权利要求1所述的降血糖益生菌组合物，其特征在于：所述唾液乳杆菌、罗伊氏乳杆菌合并苦瓜粉可进一步包括药学上可接受之载剂、赋形剂或稀释剂；并可进一步制成流体乳品、浓缩牛奶、优酪乳、酸乳、冷冻优格、乳杆菌发酵饮料、奶粉、冰淇淋、乳酪、干酪、豆浆、发酵豆浆、蔬果汁、果汁、运动饮料、甜点、果冻、糖果、婴儿食品、健康食品、动物饲料、中草药组合物或膳食补充品。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011004485.3A CN112089054A (zh) | 2020-09-22 | 2020-09-22 | 降血糖益生菌组合物 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011004485.3A CN112089054A (zh) | 2020-09-22 | 2020-09-22 | 降血糖益生菌组合物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112089054A true CN112089054A (zh) | 2020-12-18 |
Family
ID=73754962
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011004485.3A Pending CN112089054A (zh) | 2020-09-22 | 2020-09-22 | 降血糖益生菌组合物 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112089054A (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115463176A (zh) * | 2022-09-20 | 2022-12-13 | 潍坊君薇生物科技有限责任公司 | 一种降血糖组合物、制备方法及其应用 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013147457A (ja) * | 2012-01-19 | 2013-08-01 | Yakult Honsha Co Ltd | メタボリックシンドローム予防改善剤 |
| CN106070947A (zh) * | 2016-06-27 | 2016-11-09 | 山东绿爱糖果股份有限公司 | 一种功能性无糖薄荷糖及制备方法 |
| CN107523526A (zh) * | 2017-10-17 | 2017-12-29 | 无限极（中国）有限公司 | 一种罗伊氏乳杆菌及其用途 |
| CN110710660A (zh) * | 2019-09-16 | 2020-01-21 | 湖南科尔生物技术有限公司 | 含有苦瓜粉的降低血糖组合物及膳食补充剂 |
| CN111346114A (zh) * | 2018-12-21 | 2020-06-30 | 深圳市华大农业应用研究院 | 罗伊氏乳杆菌的用途 |
-
2020
- 2020-09-22 CN CN202011004485.3A patent/CN112089054A/zh active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013147457A (ja) * | 2012-01-19 | 2013-08-01 | Yakult Honsha Co Ltd | メタボリックシンドローム予防改善剤 |
| CN106070947A (zh) * | 2016-06-27 | 2016-11-09 | 山东绿爱糖果股份有限公司 | 一种功能性无糖薄荷糖及制备方法 |
| CN107523526A (zh) * | 2017-10-17 | 2017-12-29 | 无限极（中国）有限公司 | 一种罗伊氏乳杆菌及其用途 |
| CN111346114A (zh) * | 2018-12-21 | 2020-06-30 | 深圳市华大农业应用研究院 | 罗伊氏乳杆菌的用途 |
| CN110710660A (zh) * | 2019-09-16 | 2020-01-21 | 湖南科尔生物技术有限公司 | 含有苦瓜粉的降低血糖组合物及膳食补充剂 |
Non-Patent Citations (2)
| Title |
|---|
| PEI-SHAN HSIEH，等: "Lactobacillus salivarius AP-32 and Lactobacillus reuteri GL-104 decrease glycemic levels and attenuate diabetes-mediated liver and kidney injury in db/db mice", 《BMJ OPEN DIAB RES CARE》 * |
| 赵中振，等: "《百草皆药》", 30 April 2019, 中国中医药出版社 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115463176A (zh) * | 2022-09-20 | 2022-12-13 | 潍坊君薇生物科技有限责任公司 | 一种降血糖组合物、制备方法及其应用 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2774616B1 (en) | Application of roseburia in treating and preventing obesity related diseases | |
| CN110150669B (zh) | 一种适于糖尿病患者食用的益生菌组合物及其应用 | |
| EP2100604B1 (en) | Medium chain dicarboxylic acids and their derivates and metabolic disorders | |
| KR101638984B1 (ko) | 나노형 김치 유산균 | |
| Shi et al. | The effects of supplementation with blueberry, cyanidin-3-O-β-glucoside, yoghurt and its peptides on obesity and related comorbidities in a diet-induced obese mouse model | |
| CN113274481B (zh) | 一种用于调节血糖的组合物及其制备方法和应用 | |
| CN106994134B (zh) | 肠道益生菌在预防和/或治疗糖尿病及其相关疾病中的应用 | |
| CN110623182A (zh) | 一种用于治疗高尿酸及痛风的益生菌植物固体饮料 | |
| CN111084385A (zh) | 一种具有降血糖功效的益生菌制剂的功能性食品 | |
| CN109315769A (zh) | 一种用于改善人体肠内环境的组合物及其制备方法 | |
| KR20210039961A (ko) | 건강한 임산부 모유 유래 혐기성 인체 균주 및 이를 이용한 대사성 질환의 예방 또는 치료방법 | |
| CN112089054A (zh) | 降血糖益生菌组合物 | |
| CN110604748A (zh) | 益生菌联合余甘子提取物改善糖尿病及代谢综合征中的应用 | |
| KR102037897B1 (ko) | 케피어 유래 유산균 및 포도씨 분말을 포함하는 비만의 예방 또는 치료용 조성물 | |
| CN111214524A (zh) | 人参发酵物的用途 | |
| KR20140119563A (ko) | 3단 발효 공법을 통한 장내균총 개선 소재의 개발 | |
| CN109045070A (zh) | 一种防治非酒精性脂肪肝病的组合物 | |
| CN110638842A (zh) | 一种改善高血糖的益生菌组合物 | |
| CN113116941A (zh) | 一种可缓解2型糖尿病的益生菌、益生元复合制剂及其制备方法 | |
| CN106974940B (zh) | 厚壁菌类益生菌在治疗和预防肥胖及其相关疾病中的应用 | |
| KR102679094B1 (ko) | 항비만 효능을 지닌 한국인 마이크로바이옴 유래 클로스트리디움 부티리쿰 균주 및 이의 용도 | |
| Dong et al. | Research progress of probiotics and prebiotics in ajuvant therapy for diseases and prospect of their application in functional foods | |
| CN113215020B (zh) | 罗氏菌mgb-2及其应用 | |
| CN117797176B (zh) | 双孢梭菌在制备治疗非酒精性脂肪性肝病药物中的应用和一种药物 | |
| KR102619375B1 (ko) | 병풀 발효 추출물을 포함하는 비만 및 당뇨의 개선, 예방 또는 치료용 조성물 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20201218 |